The Helix Exchange https://theheliixechange.podbean.com Helix Exchange is the first business-first podcast dedicated exclusively to the world of genomics. Our mission is simple: to make the genomics revolution understandable, usable, and actionable for finance, accounting, and business professionals. Each episode cuts through the scientific noise to deliver a clear analysis of the companies, markets, technologies, and economic forces transforming genomics into one of the most important industries of our time. From sequencing and synthetic biology to precision medicine and emerging regulation—we focus on what moves markets and drives business outcomes. If you want the real story behind the genomics economy—told with the clarity, speed, and depth of a modern financial newsroom—this is your source. All business. All genomics. All the time.

]]> Tue, 24 Mar 2026 11:07:00 -0600 https://podbean.com/?v=5.5 en Copyright 2026 All rights reserved. Business 1440 episodic christinenu christinenu No false https://pbcdn1.podbean.com/imglogo/image-logo/22016644/Untitled_6_brwox.jpeg The Helix Exchange https://theheliixechange.podbean.com 144 144 The Business of Genomics: AI, Regulation & Point-of-Care Diagnostics Explained The Business of Genomics: AI, Regulation & Point-of-Care Diagnostics Explained https://theheliixechange.podbean.com/e/the-business-of-genomics-ai-regulation-point-of-care-diagnostics-explained-1771438171/ https://theheliixechange.podbean.com/e/the-business-of-genomics-ai-regulation-point-of-care-diagnostics-explained-1771438171/#comments Tue, 24 Mar 2026 11:07:00 -0600 theheliixechange.podbean.com/c1607e05-2de5-3c3e-b7bb-5fb552c511b5 How do you turn genomic innovation into commercial reality? Dr. Daniel Farkas, a leader in molecular diagnostics for over three decades, joins The Helix Exchange to break down what it really takes to bring genomic technologies from lab bench to clinical practice. In this episode: The three components of every clinical test Why reimbursement can make or break a biotech company The realities of point-of-care molecular diagnostics Multi-omics and population-scale data AI’s true opportunity in genomic analysis Why healthcare technology must be dramatically better to replace existing systems Genomics is no longer just about discovery — it’s about execution.

🎧 Listen now to understand where regulation, data, and innovation intersect in the genomics economy.

]]> How do you turn genomic innovation into commercial reality? Dr. Daniel Farkas, a leader in molecular diagnostics for over three decades, joins The Helix Exchange to break down what it really takes to bring genomic technologies from lab bench to clinical practice. In this episode: The three components of every clinical test Why reimbursement can make or break a biotech company The realities of point-of-care molecular diagnostics Multi-omics and population-scale data AI’s true opportunity in genomic analysis Why healthcare technology must be dramatically better to replace existing systems Genomics is no longer just about discovery — it’s about execution.

🎧 Listen now to understand where regulation, data, and innovation intersect in the genomics economy.

]]> How do you turn genomic innovation into commercial reality? Dr. Daniel Farkas, a leader in molecular diagnostics for over three decades, joins The Helix Exchange to break down what it really takes to bring genomic technologies from lab bench to clinical practice. In this episode: The three components of every clinical test Why reimbursement can make or break a biotech company The realities of point-of-care molecular diagnostics Multi-omics and population-scale data AI’s true opportunity in genomic analysis Why healthcare technology must be dramatically better to replace existing systems Genomics is no longer just about discovery — it’s about execution. christinenu false No 1714 1 8 full Redefining the Taxonomy of Human Disease | Dr. Lon Cardon Redefining the Taxonomy of Human Disease | Dr. Lon Cardon https://theheliixechange.podbean.com/e/redefining-the-taxonomy-of-human-disease-dr-lon-cardon/ https://theheliixechange.podbean.com/e/redefining-the-taxonomy-of-human-disease-dr-lon-cardon/#comments Tue, 17 Mar 2026 15:12:00 -0600 theheliixechange.podbean.com/56373a79-bb4d-3950-9cd6-e65d84a5c1b6 In this episode of The Helix Exchange, the guest is Dr. Lon Cardon joins to discuss the opportunity that genomics has to "redefine the taxonomy of human disease". He suggests that diseases like Alzheimer's are not a single disease but rather a spectrum that might be treated in many different ways, similar to how breast cancer has 80 different histological subtypes. This idea aligns with the concept of precision medicine, which involves thinking about diseases as "collections of related diseases but with different pathways and probably different treatment paradigms". *The Jackson Laboratory (Jax)*

  • *History:* The Jackson Laboratory, founded in 1929, invented the use of laboratory mice to study human diseases, particularly cancer. The ambition was to develop 50 different strains of mice, but today Jax has over 14,000.
  • *Current Work:* Jax works with 2,800 institutions across 68 countries, providing a cornerstone for biomedicine and animal usage. The laboratory conducts basic discovery and enables research globally, from academia to pharma.
  • *Mouse Model:* While some researchers are frustrated that animal models don't always reflect what happens in humans, Dr. Cardon does not see the end of animal models for drug discovery. He emphasizes that it would be irresponsible to test an investigational drug in humans without testing it in a "full system" to understand its effect on different organs. Jax's view is that the use of mice should change, focusing on better selection of the right tools and augmenting them with cell models and AI.

*The New York Stem Cell Foundation Acquisition*

  • *Strategy:* Jax recently acquired the New York Stem Cell Foundation (NYSCF) to augment their animal models with the latest tools, particularly in the context of drug discovery. This move aims to address "the valley of death" in drug discovery, the gap between basic science understanding of human biology and successful pharmaceutical development.
  • *Goal:* The acquisition seeks to reduce the high cost (estimated at $2 to $4 billion) and long timeline (15 years) of drug development by decreasing the number of failures. By combining mouse models with cell models and AI, Jax aims to better predict what will happen in humans, thereby increasing the probability of success and reducing cost.
  • *Pluripotent Stem Cells:* NYSCF's technology involves pluripotent stem cells, which can be taken from a person's skin or blood and converted into their primordial state, then advanced into any tissue, such as a mini beating heart or a neuron. The dream is to combine this cellular testing—which includes a person's complete DNA—with the appropriate mouse model, which may be humanized with the same DNA, to increase the chances of success in drug discovery.
  • *Standards:* Jax intends to use its experience in setting standards for reproducibility and sustainability for mice to establish similar standards in the stem cell world, which does not yet have them.

*Future Outlook*

  • *Near-Term Vision:* Dr. Cardon wants Jax to execute on the "cells plus mice underpinned by AI" link, becoming the go-to partner for all pharma companies.
  • *Baby KJ Story:* An example of the potential for accelerated treatment is the "Baby KJ story," where a newborn diagnosed with a rare disease received a personalized treatment, specifically made for the child's DNA mutations, within seven months of diagnosis.
  • *Newborn Sequencing:* Dr. Cardon believes that newborn sequencing, like the heel prick tests currently done for babies, will become a matter of time and economics because the DNA a person is born with (germline DNA) does not change and only needs to be measured once. This could help find undiagnosed or misdiagnosed rare diseases and provide information for pharmacogenomics.
  • *AI:* AI is expected to speed up science and will open up new hypotheses in linking cells and mice. However, Dr. Cardon suggests that AI works best on problems already known how to be solved and may not fully replace human interrogation in science discovery today.
  • *Optimism:* While genomics has been disappointing in translating discoveries to practice, Dr. Cardon is now "more optimistic than I have ever been" because the necessary tools (sequencing, gene editing, animal models, cell work) are available. The current challenge is execution and putting the pieces together.

Whether you’re a healthcare leader, biotech founder, investor, or genomics enthusiast, this episode offers a clear, grounded look at where personalized medicine is headed next.

]]> In this episode of The Helix Exchange, the guest is Dr. Lon Cardon joins to discuss the opportunity that genomics has to "redefine the taxonomy of human disease". He suggests that diseases like Alzheimer's are not a single disease but rather a spectrum that might be treated in many different ways, similar to how breast cancer has 80 different histological subtypes. This idea aligns with the concept of precision medicine, which involves thinking about diseases as "collections of related diseases but with different pathways and probably different treatment paradigms". *The Jackson Laboratory (Jax)*

  • *History:* The Jackson Laboratory, founded in 1929, invented the use of laboratory mice to study human diseases, particularly cancer. The ambition was to develop 50 different strains of mice, but today Jax has over 14,000.
  • *Current Work:* Jax works with 2,800 institutions across 68 countries, providing a cornerstone for biomedicine and animal usage. The laboratory conducts basic discovery and enables research globally, from academia to pharma.
  • *Mouse Model:* While some researchers are frustrated that animal models don't always reflect what happens in humans, Dr. Cardon does not see the end of animal models for drug discovery. He emphasizes that it would be irresponsible to test an investigational drug in humans without testing it in a "full system" to understand its effect on different organs. Jax's view is that the use of mice should change, focusing on better selection of the right tools and augmenting them with cell models and AI.

*The New York Stem Cell Foundation Acquisition*

  • *Strategy:* Jax recently acquired the New York Stem Cell Foundation (NYSCF) to augment their animal models with the latest tools, particularly in the context of drug discovery. This move aims to address "the valley of death" in drug discovery, the gap between basic science understanding of human biology and successful pharmaceutical development.
  • *Goal:* The acquisition seeks to reduce the high cost (estimated at $2 to $4 billion) and long timeline (15 years) of drug development by decreasing the number of failures. By combining mouse models with cell models and AI, Jax aims to better predict what will happen in humans, thereby increasing the probability of success and reducing cost.
  • *Pluripotent Stem Cells:* NYSCF's technology involves pluripotent stem cells, which can be taken from a person's skin or blood and converted into their primordial state, then advanced into any tissue, such as a mini beating heart or a neuron. The dream is to combine this cellular testing—which includes a person's complete DNA—with the appropriate mouse model, which may be humanized with the same DNA, to increase the chances of success in drug discovery.
  • *Standards:* Jax intends to use its experience in setting standards for reproducibility and sustainability for mice to establish similar standards in the stem cell world, which does not yet have them.

*Future Outlook*

  • *Near-Term Vision:* Dr. Cardon wants Jax to execute on the "cells plus mice underpinned by AI" link, becoming the go-to partner for all pharma companies.
  • *Baby KJ Story:* An example of the potential for accelerated treatment is the "Baby KJ story," where a newborn diagnosed with a rare disease received a personalized treatment, specifically made for the child's DNA mutations, within seven months of diagnosis.
  • *Newborn Sequencing:* Dr. Cardon believes that newborn sequencing, like the heel prick tests currently done for babies, will become a matter of time and economics because the DNA a person is born with (germline DNA) does not change and only needs to be measured once. This could help find undiagnosed or misdiagnosed rare diseases and provide information for pharmacogenomics.
  • *AI:* AI is expected to speed up science and will open up new hypotheses in linking cells and mice. However, Dr. Cardon suggests that AI works best on problems already known how to be solved and may not fully replace human interrogation in science discovery today.
  • *Optimism:* While genomics has been disappointing in translating discoveries to practice, Dr. Cardon is now "more optimistic than I have ever been" because the necessary tools (sequencing, gene editing, animal models, cell work) are available. The current challenge is execution and putting the pieces together.

Whether you’re a healthcare leader, biotech founder, investor, or genomics enthusiast, this episode offers a clear, grounded look at where personalized medicine is headed next.

]]> In this episode of The Helix Exchange, the guest is Dr. Lon Cardon joins to discuss the opportunity that genomics has to ”redefine the taxonomy of human disease”. He suggests that diseases like Alzheimer’s are not a single disease but rather a spectrum that might be treated in many different ways, similar to how breast cancer has 80 different histological subtypes. This idea aligns with the concept of precision medicine, which involves thinking about diseases as ”collections of related diseases but with different pathways and probably different treatment paradigms”. christinenu false No 2710 1 6 full How Genomics, AI & Precision Prescribing Are Transforming Healthcare How Genomics, AI & Precision Prescribing Are Transforming Healthcare https://theheliixechange.podbean.com/e/how-genomics-ai-precision-prescribing-are-transforming-healthcare/ https://theheliixechange.podbean.com/e/how-genomics-ai-precision-prescribing-are-transforming-healthcare/#comments Tue, 10 Mar 2026 15:05:00 -0600 theheliixechange.podbean.com/78ed08ed-394a-3006-9ad6-62ee659c9671 In this episode of The Helix Exchange, we sit down with Dr. Bernard Esquivel, physician, scientist, and CEO of Genesis, to explore how genomics, AI, and precision prescribing are reshaping healthcare. Dr. Esquivel explains why pharmacogenomics is not a silver bullet, how it must be integrated into real clinical workflows, and why access, adoption, and reimbursement are the true barriers to personalized medicine. From gene therapy and cancer treatment to AI-driven healthcare platforms and new business models, this conversation goes deep into what’s real, what’s hype, and what’s investable in genomics today. 🎯 Key topics covered: Precision prescribing vs. pharmacogenomics How AI is changing clinical decision-making Gene therapy and the future of cancer treatment Healthcare workflows, reimbursement & access Why genomics is becoming a platform, not just a science New markets in healthcare, biotech, and beyond Whether you’re a healthcare leader, biotech founder, investor, or genomics enthusiast, this episode offers a clear, grounded look at where personalized medicine is headed next.

]]> In this episode of The Helix Exchange, we sit down with Dr. Bernard Esquivel, physician, scientist, and CEO of Genesis, to explore how genomics, AI, and precision prescribing are reshaping healthcare. Dr. Esquivel explains why pharmacogenomics is not a silver bullet, how it must be integrated into real clinical workflows, and why access, adoption, and reimbursement are the true barriers to personalized medicine. From gene therapy and cancer treatment to AI-driven healthcare platforms and new business models, this conversation goes deep into what’s real, what’s hype, and what’s investable in genomics today. 🎯 Key topics covered: Precision prescribing vs. pharmacogenomics How AI is changing clinical decision-making Gene therapy and the future of cancer treatment Healthcare workflows, reimbursement & access Why genomics is becoming a platform, not just a science New markets in healthcare, biotech, and beyond Whether you’re a healthcare leader, biotech founder, investor, or genomics enthusiast, this episode offers a clear, grounded look at where personalized medicine is headed next.

]]> Dr. Esquivel explains why pharmacogenomics is not a silver bullet, how it must be integrated into real clinical workflows, and why access, adoption, and reimbursement are the true barriers to personalized medicine. From gene therapy and cancer treatment to AI-driven healthcare platforms and new business models, this conversation goes deep into what’s real, what’s hype, and what’s investable in genomics today. christinenu false No 2710 1 5 full The Future of Regenerative Medicine: Dr. Iain Drummond on Organoids, Gene Therapy & Courage The Future of Regenerative Medicine: Dr. Iain Drummond on Organoids, Gene Therapy & Courage https://theheliixechange.podbean.com/e/the-future-of-regenerative-medicine-dr-iain-drummond-on-organoids-gene-therapy-courage/ https://theheliixechange.podbean.com/e/the-future-of-regenerative-medicine-dr-iain-drummond-on-organoids-gene-therapy-courage/#comments Tue, 03 Mar 2026 15:03:00 -0700 theheliixechange.podbean.com/fd394920-ab1d-3cc1-a80c-7c44d2355eb2 In this episode of The Helix Exchange, we sit down with Dr. Iain Drummond — a pioneering biologist whose work with zebrafish has transformed how we understand kidney development, organ repair, and regenerative medicine. Drummond shares how transparency in a tiny fish led to breakthroughs that could help humans one day regrow or repair organs. We discuss the future of gene therapy, organoids, lipid nanoparticle delivery, AI-driven discovery, and what it really takes to move regenerative science from the lab to real-world therapies. He also opens up about the role of courage in scientific progress, the importance of collaboration across disciplines, and why young scientists must learn to trust what they see — even when the answers aren’t clear. Topics Covered: How zebrafish became essential to understanding human kidney regeneration Breakthroughs in organoids, stem cells, and live imaging Why gene therapy and lipid nanoparticles are reshaping medicine How AI, single-cell sequencing & biosensors accelerate discovery The commercialization challenges of regenerative biology How private investment can speed high-risk, high-return research Future applications in pets, agriculture, and environmental health Why courage — not just intelligence — drives great science Whether you're in biotech, healthcare, venture capital, genomics, or simply curious about the future of human biology, this conversation offers a rare look inside the science and business shaping the next frontier.

]]> In this episode of The Helix Exchange, we sit down with Dr. Iain Drummond — a pioneering biologist whose work with zebrafish has transformed how we understand kidney development, organ repair, and regenerative medicine. Drummond shares how transparency in a tiny fish led to breakthroughs that could help humans one day regrow or repair organs. We discuss the future of gene therapy, organoids, lipid nanoparticle delivery, AI-driven discovery, and what it really takes to move regenerative science from the lab to real-world therapies. He also opens up about the role of courage in scientific progress, the importance of collaboration across disciplines, and why young scientists must learn to trust what they see — even when the answers aren’t clear. Topics Covered: How zebrafish became essential to understanding human kidney regeneration Breakthroughs in organoids, stem cells, and live imaging Why gene therapy and lipid nanoparticles are reshaping medicine How AI, single-cell sequencing & biosensors accelerate discovery The commercialization challenges of regenerative biology How private investment can speed high-risk, high-return research Future applications in pets, agriculture, and environmental health Why courage — not just intelligence — drives great science Whether you're in biotech, healthcare, venture capital, genomics, or simply curious about the future of human biology, this conversation offers a rare look inside the science and business shaping the next frontier.

]]> In this episode of The Helix Exchange, we sit down with Dr. Iain Drummond — a pioneering biologist whose work with zebrafish has transformed how we understand kidney development, organ repair, and regenerative medicine. Drummond shares how transparency in a tiny fish led to breakthroughs that could help humans one day regrow or repair organs. We discuss the future of gene therapy, organoids, lipid nanoparticle delivery, AI-driven discovery, and what it really takes to move regenerative science from the lab to real-world therapies. He also opens up about the role of courage in scientific progress, the importance of collaboration across disciplines, and why young scientists must learn to trust what they see — even when the answers aren’t clear. christinenu false No 2725 1 4 full Could Axolotls Carry The Secrets To Change Medicine Forever? Could Axolotls Carry The Secrets To Change Medicine Forever? https://theheliixechange.podbean.com/e/could-axolotls-carry-the-secrets-to-change-medicine-forever/ https://theheliixechange.podbean.com/e/could-axolotls-carry-the-secrets-to-change-medicine-forever/#comments Tue, 24 Feb 2026 15:01:00 -0700 theheliixechange.podbean.com/f5698d98-5edd-3729-b832-9bf407fdb302 In this episode of The Helix Exchange, we dive into one of the most astonishing frontiers in regenerative biology: the axolotl, a salamander capable of regrowing limbs, organs, spinal cord, and even one-third of its brain. Our guest, Dr. Priyag Murawala, is one of the world’s leading experts on axolotl regeneration, and his research is helping uncover nature’s own blueprint for tissue repair, organ regrowth, and potential human therapies. We explore how axolotls regenerate without scarring, why fibroblasts are the “master cells” behind tissue renewal, and how these insights could drive breakthroughs in anti-fibrosis therapies, immune-guided regeneration, organ repair, AI-powered molecule discovery, and entirely new biotech industries. This conversation sits at the intersection of genomics, regenerative medicine, AI, synthetic biology, and investment strategy — revealing how foundational research today may power tomorrow’s billion-dollar opportunities. christinenu false No 1949 1 3 full The Future of Precision Medicine: Digital Twins, Multi-Omics & AI with Decode Health’s CEO The Future of Precision Medicine: Digital Twins, Multi-Omics & AI with Decode Health’s CEO https://theheliixechange.podbean.com/e/the-future-of-precision-medicine-digital-twins-multi-omics-ai-with-decode-health-s-ceo/ https://theheliixechange.podbean.com/e/the-future-of-precision-medicine-digital-twins-multi-omics-ai-with-decode-health-s-ceo/#comments Tue, 17 Feb 2026 14:59:00 -0700 theheliixechange.podbean.com/b596d244-7596-305e-a201-9896803594d8 Join us for an insightful episode of the Helix Exchange, where we dive deep into the intersection of genomics, AI, and healthcare with Dr. Chase Spurlock, CEO and co-founder of Decode Health. In this episode, we explore the transformative potential of genomics in diagnostics and drug discovery, and how advanced data platforms are accelerating research and development in the healthcare industry. christinenu false No 2040 1 2 full The Business of Genomics: AI, Regulation & Point-of-Care Diagnostics Explained The Business of Genomics: AI, Regulation & Point-of-Care Diagnostics Explained https://theheliixechange.podbean.com/e/the-business-of-genomics-ai-regulation-point-of-care-diagnostics-explained/ https://theheliixechange.podbean.com/e/the-business-of-genomics-ai-regulation-point-of-care-diagnostics-explained/#comments Mon, 16 Feb 2026 10:14:29 -0700 theheliixechange.podbean.com/db4398bc-87d0-3915-b467-11df64788b09 How do you turn genomic innovation into commercial reality? Dr. Daniel Farkas, a leader in molecular diagnostics for over three decades, joins The Helix Exchange to break down what it really takes to bring genomic technologies from lab bench to clinical practice. In this episode: The three components of every clinical test Why reimbursement can make or break a biotech company The realities of point-of-care molecular diagnostics Multi-omics and population-scale data AI’s true opportunity in genomic analysis Why healthcare technology must be dramatically better to replace existing systems Genomics is no longer just about discovery — it’s about execution. 🎧 Listen now to understand where regulation, data, and innovation intersect in the genomics economy. christinenu false No 1714 1 7 full The Shocking Truth About Oral Microbiome and Brain Health The Shocking Truth About Oral Microbiome and Brain Health https://theheliixechange.podbean.com/e/the-shocking-truth-about-oral-microbiome-and-brain-health/ https://theheliixechange.podbean.com/e/the-shocking-truth-about-oral-microbiome-and-brain-health/#comments Tue, 10 Feb 2026 14:36:35 -0700 theheliixechange.podbean.com/8aa57065-1807-3328-9682-de0e2faa0f4c Most people think about the gut microbiome—but what if the mouth is just as important, or even more influential? In this episode of The Helix Exchange, we sit down with Dr. Emily Stein, microbiologist, inventor, and co-founder at Primal Health, whose groundbreaking work reveals how oral microbes influence everything from cardiovascular disease and stroke to Alzheimer’s, cancer, autoimmune disorders, and even astronaut health. Dr. Stein shares how genomic tools, CRISPR, and multi-omics are unlocking a new understanding of the oral microbiome—and why rebalancing it may be one of the most powerful interventions for longevity and whole-body health. This conversation is eye-opening, practical, and deeply relevant to anyone interested in genomics, healthcare innovation, or improving their own healthspan. The video explores the fascinating link between the oral microbiome and overall health, suggesting that microbes in the mouth produce molecules affecting the brain. New research highlights the connection to conditions like autism and ADHD, furthering our understanding of mental health and neuroscience. Learn more about the impact of oral health on the whole body. Want to learn more about the business of Genomics? Be sure to like and subscribe for more innovative discussions.

 

Timestamps:

 00:00 – Microbes in the mouth and neurotransmitters

00:34 – Welcome to The Helix Exchange

01:00 – Emily’s first spark in genomics

02:15 – CRISPR and the power to tune microbes

02:45 – Why Emily studies the oral microbiome

03:17 – Dental procedures & unexpected systemic risks

03:39 – Cancer links: colorectal, pancreatic, Alzheimer’s

04:14 – Partnered research with Baylor

05:24 – Heart disease, stroke & oral bacteria

06:01 – Real cases: microbes eating holes in the heart

06:26 – Family transmission & pet transmission

07:00 – Ring-tailed animals, gorillas & astronaut studies

08:23 – Dysbiosis in space

08:49 – How Protektin began

09:12 – The pet version & multi-species success

10:05 – Growing beneficial microbes in the mouth

10:52 – Should all pet food have oral-protective additives?

11:28 – Oral vs gut microbiome

11:59 – Sublingual absorption & brain impacts

12:25 – Swallowing billions of microbes daily

13:16 – Optimizing your oral microbiome

14:14 – Why antiseptic mouthwash may make things worse

14:37 – How to know if your oral microbiome is off

15:09 – Bleeding gums as an early warning sign

16:05 – Keto-style shifts for oral bacteria

17:00 – Chronic inflammation & long-term consequences

18:34 – Antibiotics and autoimmune disease

19:00 – Why Emily focuses on the mouth first

19:23 – Alzheimer’s & oral pathogens

20:52 – Biggest lessons from startup setbacks

21:51 – Difficult conversations & team dynamics

22:19 – CRISPR: overhyped and underutilized

22:57 – AI & biotech markets

23:42 – Who Emily wants to work with

24:40 – Promising companies in the microbiome space

25:18 – Advice for leaders & investors

26:27 – The next decade of microbiome innovation

27:08 – Closing remarks

 

Discover the link between your mouth's microbiome and your mental health! Recent research suggests that oral health can significantly impact brain function and contribute to conditions like autism, ADHD, and depression. The oral microbiome impacts mental well-being! New research shows microbes in the mouth produce molecules that affect the brain. These molecules are linked to conditions such as autistic traits, adhd symptoms, and even depression. ]]> Most people think about the gut microbiome—but what if the mouth is just as important, or even more influential? In this episode of The Helix Exchange, we sit down with Dr. Emily Stein, microbiologist, inventor, and co-founder at Primal Health, whose groundbreaking work reveals how oral microbes influence everything from cardiovascular disease and stroke to Alzheimer’s, cancer, autoimmune disorders, and even astronaut health. Dr. Stein shares how genomic tools, CRISPR, and multi-omics are unlocking a new understanding of the oral microbiome—and why rebalancing it may be one of the most powerful interventions for longevity and whole-body health. This conversation is eye-opening, practical, and deeply relevant to anyone interested in genomics, healthcare innovation, or improving their own healthspan. The video explores the fascinating link between the oral microbiome and overall health, suggesting that microbes in the mouth produce molecules affecting the brain. New research highlights the connection to conditions like autism and ADHD, furthering our understanding of mental health and neuroscience. Learn more about the impact of oral health on the whole body. Want to learn more about the business of Genomics? Be sure to like and subscribe for more innovative discussions.

 

Timestamps:

 00:00 – Microbes in the mouth and neurotransmitters

00:34 – Welcome to The Helix Exchange

01:00 – Emily’s first spark in genomics

02:15 – CRISPR and the power to tune microbes

02:45 – Why Emily studies the oral microbiome

03:17 – Dental procedures & unexpected systemic risks

03:39 – Cancer links: colorectal, pancreatic, Alzheimer’s

04:14 – Partnered research with Baylor

05:24 – Heart disease, stroke & oral bacteria

06:01 – Real cases: microbes eating holes in the heart

06:26 – Family transmission & pet transmission

07:00 – Ring-tailed animals, gorillas & astronaut studies

08:23 – Dysbiosis in space

08:49 – How Protektin began

09:12 – The pet version & multi-species success

10:05 – Growing beneficial microbes in the mouth

10:52 – Should all pet food have oral-protective additives?

11:28 – Oral vs gut microbiome

11:59 – Sublingual absorption & brain impacts

12:25 – Swallowing billions of microbes daily

13:16 – Optimizing your oral microbiome

14:14 – Why antiseptic mouthwash may make things worse

14:37 – How to know if your oral microbiome is off

15:09 – Bleeding gums as an early warning sign

16:05 – Keto-style shifts for oral bacteria

17:00 – Chronic inflammation & long-term consequences

18:34 – Antibiotics and autoimmune disease

19:00 – Why Emily focuses on the mouth first

19:23 – Alzheimer’s & oral pathogens

20:52 – Biggest lessons from startup setbacks

21:51 – Difficult conversations & team dynamics

22:19 – CRISPR: overhyped and underutilized

22:57 – AI & biotech markets

23:42 – Who Emily wants to work with

24:40 – Promising companies in the microbiome space

25:18 – Advice for leaders & investors

26:27 – The next decade of microbiome innovation

27:08 – Closing remarks

 

Discover the link between your mouth's microbiome and your mental health! Recent research suggests that oral health can significantly impact brain function and contribute to conditions like autism, ADHD, and depression. The oral microbiome impacts mental well-being! New research shows microbes in the mouth produce molecules that affect the brain. These molecules are linked to conditions such as autistic traits, adhd symptoms, and even depression. ]]> Discover the link between your mouth’s microbiome and your mental health! Recent research suggests that oral health can significantly impact brain function and contribute to conditions like autism, ADHD, and depression. The oral microbiome impacts mental well-being! New research shows microbes in the mouth produce molecules that affect the brain. These molecules are linked to conditions such as autistic traits, adhd symptoms, and even depression. christinenu false No 1607 1 1 full